Stem Cell Transplantation for Sickle Cell Disease

An Educational Slide Set

American Society of Hematology 2021 Guidelines for Sickle Cell Disease Stem Cell Transplantation

Slide Set Authors:
Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN and
John Tisdale, MD, Cellular and Molecular Therapeutics Branch, NHLBI, National Institutes of Health, Bethesda, MD
Clinical Guidelines

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation

Julie Kanter, Robert I. Liem, Francoise Bernaudin, Javier Bolaños-Meade, Courtney D. Fitzhugh, Jane S. Hankins, M. Hassan Murad, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, John Wagner, Mark C. Walters, Teonna Woolford, Joerg J. Meerpohl, and John Tisdale

ASH Clinical Practice Guidelines on SCD

1. Cardiopulmonary and Kidney Disease
2. Transfusion Support
3. Cerebrovascular Disease
4. Acute and Chronic Pain
5. Stem Cell Transplantation
How were these ASH guidelines developed?

**PANEL FORMATION**
Each guideline panel was formed following these key criteria:
- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of conflicts of interest

**CLINICAL QUESTIONS**
10 clinically-relevant questions generated in PICO format (population, intervention, comparison, outcome)

**EVIDENCE SYNTHESIS**
Evidence summary generated for each PICO question via systematic review of health effects plus:
- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

**MAKING RECOMMENDATIONS**
Recommendations made by guideline panel members based on evidence for all factors.

Example: PICO question “Should individuals with SCD and neurologic injury, including overt stroke, SCI, or abnormal TCD, undergo MSD transplantation??”
How to use these recommendations

<table>
<thead>
<tr>
<th>STRONG Recommendation</th>
<th>CONDITIONAL Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(“The panel recommends...”)</td>
<td>(“The panel suggests...”)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>For patients</th>
<th>Most individuals would want the intervention.</th>
<th>A majority would want the intervention, but many would not.</th>
</tr>
</thead>
<tbody>
<tr>
<td>For clinicians</td>
<td>Most individuals should receive the intervention.</td>
<td>Different choices will be appropriate for different patients, depending on their values and preferences. Use shared decision making.</td>
</tr>
</tbody>
</table>
Key terms: SCD related adverse events

• Stroke
  – acute neurologic injury of the brain, retina, or spinal cord that occurs as a result of ischemia or hemorrhage that last longer than 24 hours.

• Silent cerebral infarction (SCI)/silent stroke
  – a lesion visible by magnetic resonance imaging (MRI) images with no associated findings on neurologic exam.
  – can be correlated with neurocognitive and behavioral deficits.

• Acute chest syndrome (ACS)
  – a new radiodensity on chest radiograph together with fever and/or respiratory symptoms.
Key terms in stem cell transplantation

• Matched donor
  – A donor who is at least identical to the recipient at 8/8 or 10/10 human leucocyte antigen (HLA) loci.
  – A matched donor can be a sibling (matched sibling donor or MSD) or unrelated (matched unrelated donor or MUD).

• Graft versus host disease (GVHD)
  – An immunological complication of allogeneic hematopoietic stem cell transplantation (HSCT).

• Graft failure
  – A condition wherein the blood cell counts decrease following HSCT, or the proportion of the donor cells declines below a critical level in the peripheral blood and bone marrow.
Objectives

By the end of this session, you should be able to:

• Describe recommendations for HSCT in individuals with SCD in high-income settings.
• Describe recommendations for choice of:
  – conditioning regimen
  – alternative donor
  – graft source

... in individuals undergoing HSCT for SCD.
Background and Introduction
Comparing HSCT and Standard of Care for SCD

- HSCT is a potential 1-time curative therapy for SCD.
- HSCT for SCD is evolving - new conditioning regimens, alternative donors and methods of cell harvesting, and strategies for GVHD prevention.
- Success rates after HSCT are improving, **but** survival rates in children and adults with SCD receiving disease-modifying medication and supportive therapy are improving as well.
- Short- and long-term risks of HSCT must be considered in comparison to the currently approved therapies and new potentially curative therapies under development.
Risk of HSCT related complications with age

- Viral infections (e.g., cytomegalovirus, adenovirus, and human herpesvirus 6)
- Challenging pharmacokinetics
- Almost no sickle cell disease-related mortality and a controlled morbidity
- Risk of veno-occlusive disease or sinusoidal obstruction syndrome

- Little risk of iron overload
- Few irreversible sickle cell disease-related complications
- Low risk of veno-occlusive disease or sinusoidal obstruction syndrome
- Patient can provide consent
- Fertility preservation options available

- Transplantation-associated systemic vasculopathy
- Neurotoxicity and posterior reversible encephalopathy syndrome
- Veno-occlusive disease or sinusoidal obstruction syndrome
- Acute and chronic GVHD
- Alloimmunisation
- Delayed immune reconstitution
- Graft rejection
- High transplantation-related mortality
- Irreversible sickle cell disease-related complications

Matched sibling donor HSCT, matched unrelated donor HSCT, or haploidentical HSCT*

Matched unrelated donor HSCT or haploidentical HSCT*

Haploidentical HSCT or gene editing and gene therapy options

~3  ~5  ~10  ~18  >~40

Age of the recipient (years)

Risk of transplantation-related complications

Case 1: Patient with neurological injury

A 4-year-old male with HbSS living in the United States, presents to your clinic for an annual visit. The child has recently had two abnormal TCD measurements (high MCA velocity). He is receiving hydroxyurea with good compliance since he was 2 years old. He has an HLA-matched 8-year-old sibling who has sickle cell trait. What is the next best step?

A. Repeat TCD in 1 year.
B. Continue hydroxyurea, but increase the dose.
C. Start transfusion/apheresis to reduce sickle hemoglobin level.
D. Discuss hematopoietic cell transplantation using the HLA-matched sibling as a donor.
HSCT for SCD patients with neurological injury: Recommendations

- HLA-matched related HSCT is suggested over standard of care (hydroxyurea/transfusion) in patients with SCD who have experienced an overt stroke or have an abnormal transcranial Doppler ultrasound (TCD) (conditional recommendation. very low certainty in the evidence).
- When considering transplantation for neurologic injury, children younger than age 16 years who receive matched sibling donor (MSD) HSCT have better outcomes than those older than age 16 years.
HSCT for SCD patients with neurological injury: Rationale

- Neurologic injury caused by overt stroke and SCI is a major complication of SCD.
- Up to 24% SCD patients could be affected by stroke.
- Chronic red cell transfusion (CRCT) and other supportive care therapy are useful in stroke prevention but not curative.
- Long-term CRCT is associated with risks such as alloimmunization and transfusional iron overload.
- Therefore, efforts to prevent primary or secondary stroke have focused on curative options such as HSCT.
TCD improved in those who received HSCT. New SCI developed in 3 patients who were receiving CRCT.

Case 2: Patient with severe symptoms

A 9-year-old female with HbSβ0 thalassemia has had 2 episodes of acute chest syndrome in the last 1 year. During the last episode, she required intensive care treatment and intubation. She has 3 siblings who do not have SCD. What is the next best step?

A. Continue current management.
B. Refer for gene therapy on a clinical trial.
C. Start transfusion/apheresis to reduce sickle hemoglobin level.
D. Perform HLA typing of the siblings to find a potential donor for HSCT.
HSCT for SCD patients with severe symptoms: Recommendations

• For patients with frequent pain or recurrent episodes of acute chest syndrome, consideration for transplantation should be given to patients who do not respond or have an inadequate response to standard of care, such as HU, new targeted therapies, or chronic transfusion therapies.

• For patients with SCD with an indication for HSCT who lack an MSD, suggest using transplants from alternative donors in the context of a clinical trial.
  – Alternative donor transplantation has the potential to improve or resolve disease manifestations in patients with severe SCD.
  – The risks related to transplantation complications should be balanced with benefits derived from successful transplantation.
HSCT using alternative donors

HSCT for SCD patients with severe symptoms: Rationale

• Patient-reported outcomes of pain intensity and pain impact improved post-HSCT in a subset of patients with only intermittent pain pre-HSCT.

• However, some patients (~40%) continue to experience pain post-HSCT. HSCT may not ameliorate chronic pain.

• ACS events no longer occur in patients in whom HSCT is successful.

• HSCT offers prospect of improved quality of life and prolonged survival when standard of care therapy is not successful.
Considerations for an allogeneic HSCT (conditional recommendations)

• Suggest using either total-body irradiation (TBI) #400 cGy or chemotherapy-based conditioning regimens for allo HSCT.
• In children with MSD, use myeloablative conditioning regimens over reduced intensity conditioning (RIC).
• In adults with MSD, use non-myeloablative conditioning over RIC.
• In patients with an indication, perform transplant at an earlier age than at an older age (no recommendation if no MSD available, impact of age on outcome may be related to conditioning regimen used).
• If HLA-identical sibling cord blood unit is available with good cell dose and viability, it is preferred over bone marrow.
Considerations for an allogeneic HSCT: Conditioning regimen

• Chemotherapy-based myeloablative conditioning with busulfan and cyclophosphamide, with or without serotherapy with anti-thymocyte globulin, is the standard of care for pediatric patients with SCD undergoing MSD HSCT.
  – Incidence of graft failure is higher after RIC compared to myeloablative conditioning.

• Nonmyeloablative regimens based on low-dose TBI have been developed and seem highly effective in reversing the disease in adult patients.
  – Better tolerated than chemotherapy-based conditioning in adults.
  – Potential for fertility preservation.
Age at HSCT and relationship to conditioning intensity

- With **myeloablative conditioning**, EFS was highest in children younger than age 13 years and with an MSD.
- Patients older than age 13 years had not only lower EFS but also lower OS and higher chronic GVHD risk.
- With myeloablative conditioning, the risk of chronic GVHD is significantly higher in those older than 15 years of age.

- **Nonmyeloablative conditioning** demonstrated no chronic GVHD or associated transplantation-related mortality.
- However, EFS was only 87%, because 13% had graft rejection.
### Table 1. Risk score based on age at transplantation and type of donor (training cohort)

<table>
<thead>
<tr>
<th>Age, y</th>
<th>Age score</th>
<th>Type of donor</th>
<th>Donor score</th>
<th>Total score</th>
<th>3-year probability/incidence % (95% CI)</th>
<th>EFS</th>
<th>Death without graft failure</th>
<th>Graft failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤12</td>
<td>0</td>
<td>HLA matched sibling</td>
<td>0</td>
<td>0</td>
<td>92 (89.94)</td>
<td>2 (0-4)</td>
<td>6 (4-9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>HLA mismatched relative</td>
<td>2</td>
<td>2</td>
<td>62 (43.76)</td>
<td>8 (2-19)</td>
<td>30 (15-47)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>Matched unrelated donor</td>
<td>1</td>
<td>1</td>
<td>83 (69.91)</td>
<td>8 (2-18)</td>
<td>8 (2-18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>Mismatched unrelated donor</td>
<td>2</td>
<td>2</td>
<td>68 (55.79)</td>
<td>5 (1-13)</td>
<td>27 (16-38)</td>
<td></td>
</tr>
<tr>
<td>≥13</td>
<td>1</td>
<td>HLA matched sibling</td>
<td>0</td>
<td>1</td>
<td>87 (81.92)</td>
<td>7 (4-11)</td>
<td>5 (2-10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>HLA mismatched relative</td>
<td>2</td>
<td>3</td>
<td>52 (38.65)</td>
<td>10 (4-18)</td>
<td>38 (24-51)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Matched unrelated donor</td>
<td>1</td>
<td>2</td>
<td>50 (34.64)</td>
<td>29 (17-43)</td>
<td>21 (10-33)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Mismatched unrelated donor</td>
<td>2</td>
<td>3</td>
<td>49 (31.66)</td>
<td>23 (9-40)</td>
<td>28 (13-44)</td>
<td></td>
</tr>
</tbody>
</table>

Cord blood transplantation

- Neutrophil and platelet recovery delayed after cord blood transplantation compared to bone marrow transplantation, but no increase in infections or non-engraftment.
- Trend towards lower acute and chronic GVHD with cord blood transplantation.
- No difference in overall survival or event free survival with cord blood transplantation.
- Hence cord blood transplantation preferred over bone marrow for SCD, provided sufficient cell dose is available.
Good Practice Statements

1. Ensure that potential patients have been seen and counseled by an SCD specialist in addition to a specialist in HSCT to review all available treatment options.

2. Providers should be adequately trained in the specialized care required by SCD patients, including supportive care, which differs from that of other disease states.

3. Disease and transplantation-related outcomes should be monitored in the short (<2 years) and long term (10-15 years) in all patients after HSCT.

4. Care providers should consider health literacy levels of patients and their families when advising on HSCT.

5. Care providers should consider the burdens of the HSCT procedure on patients and their families.

6. Shared decision making between patients and providers is suggested to establish optimal HSCT plans.
Acknowledgements

- ASH guideline panel members
- Mayo Clinic Evidence-Based Practice Research Program
- ASH support team: Starr Webb, Kendall Alexander, Robert Kunkle
- See more about the ASH SCD guidelines: https://hematology.org/SCDguidelines

Disclosures: Akshay Sharma is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287) and by Novartis (NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Akshay Sharma’s institution. Akshay Sharma has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education.